Irreversible leukoencephalopathy after reduced-intensity stem cell transplantation in a dyskeratosis congenita patient with TINF2 mutation

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 4, 2013, Pages

  Isoda, Takeshi ^a   Mitsuiki, Noriko ^a   Ohkawa, Teppei ^a   Kaneko, Setsuko ^a   Endo, Akifumi ^a   Ono, Toshiaki ^a   Aoki, Yuki ^a   Tomizawa, Daisuke ^a   Kajiwara, Michiko ^a   Araki, Satoshi ^a   Nagasawa, Masayuki ^a   Morio, Tomohiro ^a   Takagi, Masatoshi ^a   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Complication; Dyskeratosis congenita; Encephalopathy; Hematopoietic stem cell transplantation; Sequelae; TINF2

Indexed keywords

ARGININE; BILIRUBIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYSTEINE; CYTOSINE; DIAZEPAM; FLUDARABINE; GENOMIC DNA; HEMOGLOBIN; ISOSORBIDE DINITRATE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MIDAZOLAM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PHENOBARBITAL; PREDNISOLONE; TACROLIMUS; THROMBOMODULIN; THYMINE; THYMOCYTE ANTIBODY; TELOMERE BINDING PROTEIN; TINF2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW HYPOPLASIA; BRAIN ATROPHY; BRAIN EDEMA; CASE REPORT; CHILD; CHIMERA; CONTROLLED STUDY; CONVULSION; DETERIORATION; DIARRHEA; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKERATOSIS CONGENITA; EPILEPTIC STATE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; GENE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INTELLIGENCE QUOTIENT; LEUKOCYTE COUNT; LEUKOPLAKIA; LIVER DYSFUNCTION; MALE; MENTAL DEFICIENCY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PHYSICAL EXAMINATION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; RASH; REDUCED INTENSITY CONDITIONING; REHABILITATION CARE; RESPIRATION DEPRESSION; RISK FACTOR; SCHOOL CHILD; SEQUENCE ANALYSIS; TELOMERE SHORTENING; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TINF2 GENE; BLOOD; GENETICS; LEUKOENCEPHALOPATHY; METHODOLOGY; MUTATION; PRESCHOOL CHILD;

CHILD, PRESCHOOL; DYSKERATOSIS CONGENITA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOENCEPHALOPATHIES; MALE; MUTATION; TELOMERE-BINDING PROTEINS;

MLCS; MLOWN;

EID: 84878660541     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318279e5ca     Document Type: Article

References (21)

1. Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol. 2009;145:164-172.
2. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood. 2008;111:4446-4455.
3. Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110:1439-1447.
4. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480-486.
5. Savage SA, Giri N, Baerlocher GM, et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet. 2008;82:501-509.
6. Walne AJ, Vulliamy T, Beswick R, et al. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood. 2008;112:3594-3600.
7. de la Fuente J, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant. 2007;11:584-594.
8. Brazzola P, DuvalM, Fournet JC, et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant. 2005;36:1103-1105, author reply 1105.
9. Amarasinghe K, Dalley C, Dokal I, et al. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant. 2007;40:913-914.
10. Baerlocher GM, Vulto I, de Jong G, et al. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc. 2006;1:2365-2376.
11. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41.
12. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011;9(suppl 1):168-173.
13. Rocha V, Devergie A, Socie G, et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol. 1998;103:243-248.
14. Dietz AC, Orchard PJ, Baker KS, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 2011;46:98-104.
15. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115:1098-1105.
16. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. Am J Neuroradiol. 2008;29:1036-1042.
17. Morris EB, Laningham FH, Sandlund JT, et al. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer. 2007;48:152-159.
18. Lucchini G, Grioni D, Colombini A, et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51: 629-633.
19. Minn AY, Fisher PG, Barnes PD, et al. A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2007; 48:213-217.
20. Zeng L, Yan Z, Ding S, et al. Endothelial injury, an intriguing effect of methotrexate and cyclophosphamide during hematopoietic stem cell transplantation in mice. Transplant Proc. 2008;40:2670-2673.
21. Merkle CJ, Moore IM, Penton BS, et al. Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs. 2000;2:5-14.